ASML vs. LLY: ASML vs. Eli Lilly Stock Comparison

Company Profile

ASML (ASML) is classified in the Information Technology sector (Semiconductors & Semiconductor Equipment), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.

Eli Lilly (LLY) trades as ordinary local shares, while ASML (ASML) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

ASML (ASML) has an aggressive beta of 1.80, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.40 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but ASML (ASML) at 65.64% is the standout with ROE above its industry range; Eli Lilly (LLY) at 86.02% also sits in the top quartile.

Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and ASML (ASML) at 34.14% also retains a top-quartile share.

Both ASML (ASML) at 44.36% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both ASML (ASML) at 15.58% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while ASML (ASML) at 28.43% is closer to the peer norm — faster per-share earnings growth for LLY.

Growth Metrics

Financial Strength

Both ASML (ASML) at 1.49 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ASML (ASML) at 0.09 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

ASML (ASML) at 0.55% pays an industry-typical yield; Eli Lilly (LLY) at 0.49% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.

Both pay out more than their industries’ typical bands, and LLY more so: ASML (ASML) at 22.26% sits above the band, while Eli Lilly (LLY) at 21.71% exceeds every peer in its group.

Dividend Metrics

Valuation

ASML (ASML) at 35.06 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

Eli Lilly (LLY) at 13.95 is priced about in line with its industry on P/S ratio, while ASML (ASML) at 13.91 sits in the pricier quartile — ASML costs more per dollar of sales.

Measured against book value, both ASML (ASML) at 1,223.36 and Eli Lilly (LLY) at 29.96 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics